{"document_type": "article", "byline": {"person": [{"firstname": "Steven", "organization": "", "lastname": "SOLOMON", "role": "reported", "rank": 1, "middlename": "Davidoff"}], "original": "By STEVEN DAVIDOFF SOLOMON"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Steven Davidoff Solomon Deal Professor column runs through various explanations for turmoil at Valeant Pharmaceuticals International, once Wall Street darling.", "multimedia": [{"type": "image", "url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbWide.jpg", "legacy": {"wide": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "608"}, "width": 600, "subtype": "xlarge", "height": 608}, {"type": "image", "url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"kicker": "Deal Professor", "content_kicker": "Deal Professor", "print_headline": "Explaining Valeant: The Main Theories", "main": "Explaining Valeant: The Main Theories"}, "print_page": "5", "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "McKinsey & Co", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Stocks and Bonds", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "4", "name": "subject"}], "snippet": "Reasons given for the turmoil at Valeant Pharmaceuticals include its cuts in research and development, its drug pricing and investors\u2019 influence.", "source": "The New York Times", "lead_paragraph": "Reasons given for the turmoil at Valeant Pharmaceuticals include its cuts in research and development, its drug pricing and investors\u2019 influence.", "word_count": "1271", "pub_date": "2016-03-30T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/03/30/business/dealbook/explaining-valeant-the-main-theories.html", "_id": "56fb020f38f0d816b6b7e254"}